CON Concentra Group Holdings Parent, Inc.

CIK 0002014596 27 ready 8-Ks latest August 6, 2026, 4:49 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 27

Latest filing August 27, 2026, 4:50 PM ET

Top materiality 0.85

Event mix earnings ×10 · other_material ×6 · other ×5

Sentiment 13 pos · 0 neg · 14 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for CON

Highest-materiality recent filing

Concentra beats 2025 guidance; Q4 revenue +15.9% to $539M, FY revenue +13.9% to $2.16B

January 28, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Q4 2025 revenue $539.1M (+15.9%), net income $36.2M (+58.7%), adjusted EBITDA $95.3M (+22.9%).
Full year 2025 revenue $2,163.4M (+13.9%), adjusted EBITDA $431.9M (+14.6%), EPS $1.30 (adj $1.37).

Read filing →

August 6, 2026, 4:49 PM ET earnings materiality 0.80 positive item 2.02 item 5.02 item 7.01 item 8.01 item 9.01

Concentra Q2 revenue up 10%, net income up 46%; raises FY guidance; CEO succession to DiCanio

Q2 revenue $606M (+10% YoY), net income $67.3M (+45.7%), adjusted EBITDA $140.9M (+22.5%).
May 7, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 8.01 item 9.01 ◈ Earnings Releases ×2

Concentra Q1 revenue $569.6M (+13.7%); raises FY26 guidance; declares $0.0625 dividend

Revenue $569.6M (+13.7% YoY); net income $52.3M (+28.7%); EPS $0.39, adjusted EPS $0.40.
February 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q4 revenue +15.9% to $539M; guides FY2026 rev $2.25B-$2.35B

Q4 2025 net income $36.2M (+58.7% YoY); EPS $0.27, adjusted EPS $0.28.
January 28, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Concentra beats 2025 guidance; Q4 revenue +15.9% to $539M, FY revenue +13.9% to $2.16B

Q4 2025 revenue $539.1M (+15.9%), net income $36.2M (+58.7%), adjusted EBITDA $95.3M (+22.9%).
November 6, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q3 revenue +17% to $572.8M, EPS $0.38, raises FY2025 guidance

Revenue $572.8M (+17% YoY); net income $49.8M; EPS $0.38; adjusted EPS $0.39.
August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q2 revenue $550.8M (+15.2%), raises FY 2025 guidance

Q2 revenue $550.8M (+15.2% YoY), net income $46.2M, EPS $0.35, adjusted EPS $0.37.
June 2, 2025, 7:59 PM ET M&A materiality 0.65 positive item 2.01 item 7.01 item 9.01 ◈ M&A Transactions

Concentra closes $55M acquisition of Pivot Onsite Innovations, doubling onsite clinics to ~350

Acquired all equity of Onsite Innovations (Pivot Onsite) for $55M, using cash and revolver.
May 7, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q1 revenue $500.8M (+7.1% YoY), Adj. EBITDA $102.7M (+6.8%), raises 2025 guidance

Net income $40.6M ($0.30 EPS); adjusted EPS $0.32, down from $0.49 YoY due to higher interest from IPO recap.
April 21, 2025, 7:59 PM ET M&A materiality 0.65 positive item 1.01 item 7.01 item 9.01

Concentra to acquire Pivot Onsite Innovations for $55M; doubles onsite health segment

$55M acquisition of Pivot Onsite Innovations from Athletico Physical Therapy.
March 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 1.01 item 2.01 item 2.02 item 2.03 item 8.01 item 9.01 ◈ M&A Transactions

Concentra Q4 revenue +5.5% to $465M, adjusted EBITDA +13.6%; closes $265M Nova acquisition; declares $0.0625 dividend

Q4 revenue $465.0M (+5.5% YoY); net income $22.8M ($0.17 EPS).
January 23, 2025, 6:59 PM ET M&A materiality 0.80 positive item 1.01 item 2.02 item 9.01

Concentra to acquire Nova Medical Centers for $265M; Q4 revenue $465M (+5.5% YoY)

Agreement to buy all membership interests of Nova Medical Centers for $265M; expected close in Q1 2025.
November 26, 2024, 6:59 PM ET other material materiality 0.75 neutral item 5.01 item 9.01 ◈ M&A Transactions

Concentra completes spin-off from Select Medical; distributes 104M shares to Select stockholders

Select Medical distributed 104,093,503 shares of Concentra common stock (81.7% ownership) to its stockholders.
October 31, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 8.01 item 9.01

Concentra Q3 revenue $489.6M (+3.3%); Adj. EBITDA $101.6M; declares $0.0625 dividend

Net income $45.8M, EPS $0.37; Adjusted EBITDA margin 20.7% vs 20.9% YoY.
August 1, 2024, 7:59 PM ET other material materiality 0.80 neutral item 1.01 item 2.03 item 5.02 item 5.03 item 9.01

Concentra completes IPO, enters $1.25B credit facility and issues $650M notes

Completed IPO of 22.5M shares at $23.50/share, net proceeds ~$499.7M.
August 1, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

Concentra Q2 revenue up 2.3% to $477.9M; completed IPO on July 26

Net income $53.1M (-1.8% YoY); EPS $0.50 (-2.0% YoY); Adjusted EPS $0.49.

Executive changes

Departed

Dr. John R. Anderson

Executive Vice President and Chief Medical Officer

CON · Concentra Group Holdings Parent, Inc.

Effective: 2026-12-31
Filed: July 10, 2026, 4:53 PM ET

Dr. John R. Anderson notified Concentra Group Holdings Parent, Inc. (the “Company”) of his retirement from his position as Executive Vice President and Chief Medical Officer of the Company effective as of December 31, 2026.

Earnings & guidance

2026-Q1 EPS reported $0.39 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

13 positive 0 negative 14 neutral

source · CON on sec.gov